Statin Combined with Amlodipine Treats Primary Aldosteronism
A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment
Third Military Medical University
180 participants
Sep 10, 2024
INTERVENTIONAL
Conditions
Summary
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Eligibility
Inclusion Criteria1
- Clinical diagnosis of primary aldosteronism
Exclusion Criteria4
- Allergy to drugs in this study
- Pregnancy
- Severe liver and kidney dysfunction
- Mental illness
Interventions
6-month treatment of Simvastatin combined with Amlodipine besylate
6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
6-month treatment of Amlodipine besylate combined with Spironolactone
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06523465